| Regimen |
Response Rate > or = 50% in PSA |
MDR-median duration of response MDS-median duration
of survival |
Reference and Year. See above listings for complete
reference information. |
Comments |
| Adriamycin + Cytoxan |
46% (16/35) |
MDS 11 months In responders it was 23 months |
Small et al. JCO 1996 |
Adria 40/m2 ; Cytoxan 800-2000 mg/m2
q 21 days with G CSF support + dose escalation |
| Adria + 5-FU (CI) |
61% (11/18) |
MDR 7+ months with all pts still responding |
Koch et al. Proc Am Soc Clin Oncol 1992 |
Adria 15 mg/m2 q wk + 5-FU 250/m2 daily by continuous
infusion pump |
| Adriamycin + Ketoconazole ** |
55% (21/38) |
MDS 17.3+ months if PSA > 80% then 20+ months MDR 7.1
months (3-26.9); 14 months if PSA decline > or = 80% |
Sella et al. JCO 12:683-688, 1994 |
Adria 20 mg/m2 over 24 hours a week + Keto (1200/d) +
HC |
| Logothetis (Adria, Nizoral, Emcyt, Velban) ** |
67% (31/46) 24/46 (52%) 80% or greater 12/16 soft tissue
responses |
MDR 8.4 months MDS 19 months MDS of PSA responders not
reached; for nonresponders MDS 13 months |
Ellerhorst et al. Clin Ca Res 1997 |
Adria HDK qo wk alt with Emcyt Vlb qo wk |
| Cytoxan, 5-FU, DES, Castration * |
36 patients |
Cumulative survival at 11 years is 56% |
Servadio et al. Urology 1987 |
Orchx, breast RT, DES 3 mg/d, 5-FU + Cytx 10mg/kg/wk x 2
yrs, 5mg/kg/wk q 3 wks for yr 3-4; q 4 wks in yr 5 |
| Cytoxan high dose * |
|
Responders with MDS 18.6 months vs 8.1 in
non-responders |
Chlebowski et al. Cancer 1978 |
Cytx 800-1200mg/m2 q 3 wks vs Cytx 150-200 mg/m2 po 3-6 +
5-FU + Adria 30-50/m2 day 1 |
| Cytoxan high dose i.v. * |
75% (3/4) African Americans |
MDS 12.5 months |
Smith et al. Proc Am Soc Clin Oncol 1996 |
|
| Cytoxan + DPPE (histamine antagonist) |
50% (10/20) |
No data |
Brandes LJ, et al. JCO 1995 |
DPPE 6 mg/kg i.v. over 80 minutes; Cytx 600-800 mg/m2 over
last 20 min of DPPE infusion q wk x 4, 1 week rest, then 2 out
of every 3 weeks treatment |
| HDK, HC + Oral Cytoxan |
78% (21/27) |
MDR 9 months |
Pavlick et al. Proc Am Soc Clin Oncol 1996 |
HDK 400 tid, HC 20/10, Cytx 100 mg/m2 x 14 of 28 days; q 28
days |
| Keto + HC after AAWR |
30/48 (62.5%) |
MDR 3+ months (range 3.2-12.75+) |
Small EJ, Baron AD. J Urol 1997 |
23/48 (48%) > 80% fall in PSA |
| Ketoconazole + Hydrocortisone + AAWR * |
11/20 (55%) |
MDR 8.5 months MS 19 months |
Small EJ, Baron AD, Bok R. Cancer 1997 |
10/20 had > 80% fall in PSA |
| Emcyt + Navelbine vs NVB monoRx Chemo naïve * |
NVB: 19/47 (40%) NVB + E 27/40 (68%) 50% PSA |
MDS 8 months MDS 12 months |
Oudard et al. Proc Am Soc Clin Oncol 1999 |
NVB 25/m2 days 1, 8, E 600 mg/m2 qd every 21 days |
| Emcyt + VP-16 * |
53% (9/17) African American 53% (41/78) (Anglos) |
MDS 12.8 months MDS 12 months |
Smith DC, et al. Proc Am Soc Clin Oncol 1996 |
|
| Emcyt + VP-16 * |
58% (30/52) |
MDS 13 months |
Dimopoulos MA, et al. Urology 1997 |
|
| Emcyt + VP-16 ** |
85.7% (30/35) |
MDS (actuarial) 32 months |
Cruciani, Proc Am Soc Clin Oncol 1998 |
|
| Emcyt + VP16 + Carbo |
61% 11/18 |
No data |
Frank et al. Proc Am Soc Clin Oncol 1995 |
VP 100 × 14 or 120/m2 × 3; Carbo 5(CrCl + 25),
emcyt 10/kg/d × 14 |
| Emcyt + velban |
54% (13/24) |
MDR 7 months (4-10) |
Seidman et al. J Urol 1992 |
emcyt 10 mg/kg velban 4 mg/m2 |
| Emcyt + Taxol (3 hour weekly) |
9/14 (64%) > OR = 50% PSA and 7/14 (50%) > OR = 80%
PSA |
No data |
Haas et al. Proc Am Soc Clin Oncol 1999 |
Taxol weekly × 6 q 8 wks at 60-107mg /m2 /wk; E 280
mg bid × 3 days of each week × 6 wks |
| Emcyt + Taxol + Carbo |
19/26 (73%) with > OR = to 50% PSA; 14/26 (54%) with
> OR = to 80% PSA; 6/26 (23%) nl PSA |
MDR 6+ months (5+ -12+); measurable regression 9/14
(64%) |
Kelly et al. AUA 1999; pts with AIPC had 2x as much DVT as
second arm with ADPC (18% vs 9%) (166) |
26 pts with AIPC; Taxol 100/m2 weekly, E and C monthly |
| EMP + Taxotere + DXM after DXM failure |
7/8 (88%) with > OR = 50% PSA ; 5/8 (63%) with > OR =
75% PSA |
No data |
Shelton et al. Proc Am Soc Clin Oncol 1998 |
12 pts who rec'd DXM first, failed and then on EMP +
Taxotere + Dex |
| Emcyt + Taxol ** |
53.1% (17/32) |
MDR 9.25 months MDS 17.25 months |
Hudes GR, et al. JCO 1997 |
Taxol 120/m2 over 96 hrs q 3 wks + Emcyt at 600/m2/d |
| Emcyt + Taxotere Emcyt + Navelbine |
77%; 55% |
No data |
Natale et al. Proc Am Soc Clin Oncol 1998 |
Various dose regimens of weekly T or Navelbine |
| Emcyt + Taxotere weekly |
14/18 (77.8%) for > or = 50% PSA ; 9/18 (50%) for >
or = 75% PSA |
No data |
Natale et al. Proc Am Soc Clin Oncol 1999 |
Weekly taxotere at doses ranging 20-35 mg/m2 week for 6 of
8 weeks. EMP doses days 1-3 420 mg first 4 doses, 280 mg last 5
doses; DXM 4 bid day before, of and after T |
| Emcyt + Taxotere ** |
20/32 (63%) with > or = 50% PSA |
MDS > 1 yr; not yet reached |
Petrylak et al. JCO 1999 |
Multiple dose levels of Taxotere with optimal dose at 70
mg/m2 on day 2 + emcyt 280 mg tid days 1-5, decadron 20 mg
midnight, 6 am and just before Taxotere |
| Emcyt + Taxotere Emcyt 10mg/kg x 5 days + low dose HC Chemo
naive |
11/19 (57.9%) > 50% decline in PSA; 7/11 (63.6%) >
75% decline in PSA |
No data; only 2 cycles of Rx |
Savarese et al. Proc Am Soc Clin Oncol 1999 |
Taxotere at 70mg/m2 q 3 weeks on day 2 |
| Emcyt + Taxotere Chemo naïve |
16/19 (84%) > or = 50% PSA drop; 13/19 (68%) with >
or = 80% PSA drop |
MDR if 50% drop 5.5 m(0.75 + -16 months); if 80% or more
drop: 5 months (0.75-13 months) |
Weitzman et al. Proc Am Soc Clin Oncol 1999 |
Taxotere 70 mg/m2 Emcyt 280 tid × 5 days; DXM 20 po
12, 6 and just before chemo q 3 wks |
| Taxotere Chemo naïve * |
16/35 (45%) > 50% PSA decline; 7/35 > 80% |
MDR 9 months MDS 12 months |
Picus et al. Proc Am Soc Clin Oncol 1999 |
75 mg/m2 q 3 wks No Emcyt |
| DES 3 mg a day + Coumadin |
64% (9/14) with PSA of > 75% |
MDR 8 months (2-24) |
Jazieh et al. Proc Ann Meet Am Ass Ca Res 1994 |
Post-orchiectomy patients |
| DES 1 mg a day ** |
62% if only 1 prior hormone therapy |
Median survival at 3 years not reached; survival rate at 2
years is 63% |
Smith DC, et al. Urology 1998 |
Patients off LHRH and also had AAWR |
| DES + HC |
54% (36/56) |
MDR 8.5 months |
Harland et al. Proc Am Soc Clin Oncol 1998 |
HC 20 bid, DES 1 mg qd, Coumadin 1 mg qd |
| 5-FU + IFN ** |
43% (9/21) |
MDS 18 months |
Shinohara N, et al. Prostate 1998; 57% with partial or
complete disappearance of bone pain (178) |
5-FU 600 mg/m2 × 5 days, bolus FU at 600/m2 days 15,
22; IFN 3 m units days 1, 3, 5,15, 22 q 4 weeks |